Novartis one-time gene therapy demands ‘rethink’ of healthcare costing
Luxturna has been approved by Europe but the treatment may require a revaluation of cost-effectiveness evaluations, suggests Novartis UK CSO.
Archives for November 27, 2018
UK vows to speed up drug review in return for 2% sales cap
UK government and ABPI have agreed a deal to limit branded drug sales growth to 2%, potentially reducing the cost of medicine by £930m.
GE to open fibre-based chromatography facility in UK
The Stevenage facility will produce a fibre-based purification platform for the manufacture of biopharmaceuticals, gene therapies and viral vectors.